{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-256101","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.207369+00:00","generated_at":"2026-05-30T02:01:06.154905+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics","bullets":["James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.","Board appointed Rachel King as Class II director to fill the vacancy; term expires at 2027 annual meeting.","King is independent and will serve on Compensation & Human Capital Management Committee.","King receives standard non-employee director compensation including option for 60,000 shares at $3.64 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-256101","json":"https://secwatch.observer/filing/0001193125-24-256101.json","markdown":"https://secwatch.observer/filing/0001193125-24-256101.md","text":"https://secwatch.observer/filing/0001193125-24-256101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/d875361d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:01:06.154905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e58232dbc","claim":"Rachel King was appointed as director at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"fc7f201149","claim":"James J. Collins resigned as director at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}